Your browser doesn't support javascript.
loading
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Pal, Sumanta K; Bajorin, Dean; Dizman, Nazli; Hoffman-Censits, Jean; Quinn, David I; Petrylak, Daniel P; Galsky, Matthew D; Vaishampayan, Ulka; De Giorgi, Ugo; Gupta, Sumati; Burris, Howard A; Soifer, Harris S; Li, Gary; Wang, Hao; Dambkowski, Carl L; Moran, Susan; Daneshmand, Siamak; Rosenberg, Jonathan E.
Afiliación
  • Pal SK; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
  • Bajorin D; Genitourinary Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Dizman N; Department of Medicine, Weill Cornell Medical College, New York, New York.
  • Hoffman-Censits J; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.
  • Quinn DI; Departments of Medical Oncology and Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Petrylak DP; University of Southern California Norris Comprehensive Cancer Center Keck School of Medicine at USC, Los Angeles, California.
  • Galsky MD; Department of Medicine, Division of Oncology, Yale School of Medicine, New Haven, Connecticut.
  • Vaishampayan U; Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, The Mount Sinai Hospital, New York, New York.
  • De Giorgi U; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
  • Gupta S; Department of Medical Oncology, Scientific Institute of Romagna for the Study and Treatment of Cancer, IRCCS, Meldola, Italy.
  • Burris HA; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Soifer HS; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee.
  • Li G; Department of Translational Medicine, QED Therapeutics Inc, San Francisco, California.
  • Wang H; Department of Translational Medicine, QED Therapeutics Inc, San Francisco, California.
  • Dambkowski CL; Department of Biostatistics and Data Management, QED Therapeutics Inc, San Francisco, California.
  • Moran S; Department of Strategy and Operations, QED Therapeutics Inc, San Francisco, California.
  • Daneshmand S; Department of Clinical Development, QED Therapeutics Inc, San Francisco, California.
  • Rosenberg JE; Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Cancer ; 126(11): 2597-2606, 2020 06 01.
Article en En | MEDLINE | ID: mdl-32208524
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Pirimidinas / Neoplasias de la Vejiga Urinaria / Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos / Ácidos Nucleicos Libres de Células / Mutación Tipo de estudio: Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Fenilurea / Pirimidinas / Neoplasias de la Vejiga Urinaria / Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos / Ácidos Nucleicos Libres de Células / Mutación Tipo de estudio: Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos